

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
August 1, 2007
MINUTES

1. Call To Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, August 1, 2007.

2. Welcome

Dr. LaCroix called the meeting to order and welcomed members, guests, and staff members.

Tracy Russell welcomed all on behalf of SCPhA.

Dr. LaCroix opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Joe Horvath, M.D.

Jerome Kurent, M.D.

Robin K. LaCroix, M.D.

Jim Lindsay, M.D.

Tan Platt, M.D.

George E. Vess, Pharm. D.

Thomas Phillips, R.Ph.

Harry Wright, M.D.

DHHS Staff Present:

Marion Burton, M.D.

James M. Assey, R.Ph.

April Smith

Other Representation:

First Health Services. – Mary Roberts, R.Ph.

Pharmaceutical Industry Speakers

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, May 2, 2006.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

The rules for public comment were outlined. Dr. LaCroix instructed the speakers that presentations would be limited to three minutes. The Committee members' meeting packets included the speakers' curriculum vitae and signed disclosure declaration forms that were submitted prior to the meeting. The following speakers (in order of appearance) discussed the drugs listed below.

Company	Speaker	Drug
Glaxo Smith Kline	Lorie Mody, Pharm.D. Senior Medical Information Scientist, Neurosciences, Glaxo Smith Kline	Requip®
Boehringer Ingelheim	Ann Corbin, B.S.,M.S. National Medical Scientist, CNS Division, Boehringer Ingelheim Pharmaceuticals, Inc.	Mirpaex®
UCB Pharma Inc	Nigel Isaacs, Pharm.D. Medical Science Liaison UCB Pharma Inc	Neupro®
Bayer HC Pharmaceuticals	Allen R. Geiwitz, M.S., Pharm.D., Medical Science Liaison Scientific Affairs, Neuroscience, Mid-Atlantic Area Bayer Healthcare Pharmaceuticals Inc.	Betaseron®
EMD Serono	James Thomas, B.A. EMD Serono	Rebif®
Sanofi-Aventis	J. Christopher Spell U.S. Medical Affairs, Oncology Sanofi-Aventis	Uraxotral®
Allergan	Charles "Tim" Lewis, B.S. Pharm, R.Ph., C.Ph., MBA, Founder, Clinical Pharmacist, Managing Partner, Jasos® Group, LLC	Tazorac®

C. Drug Classes for Review and Re-Review

Mary Roberts, R.Ph., First Health Services Corporation, led the discussion for the following drug classes:

- Receptor Selective NSAIDs
- Multiple Sclerosis Agents
- Combination Benzoyl Peroxide/Clindamycin Products
- Topical Retinoids
- Alpha Blockers for BPH
- Topical Agents for Psoriasis
- Non-Ergot Dopamine Receptor Agonists

The chart below represents the recommendations for the P & T Committee:

NO PA REQUIRED "PREFERRED"	PA REQUIRED
<i>Receptor Selective NSAID's</i>	
CELEBREX® MELOXICAM	MOBIC®
<i>Multiple Sclerosis Agents</i>	
AVONEX® AVONEX ADMINISTRATION PACK® BETASERON® COPAXONE® REBIF®	
<i>Combination Benzoyl Peroxide/Clindamycin Products</i>	
BENZACLIN®	DUAC®
<i>Topical Retinoids</i>	
RETIN-A MICRO® TRETINOIN	AVITA® DIFFERIN® RETIN-A® RETIN-A MICRO® PUMP TAZORAC®
<i>P&T committee recommended electronic step edit to allow Differin® with preferred agent in 1 years' history</i>	
<i>Alpha Blockers for BPH</i>	
FLOMAX® UROXATRAL®	
<i>Topical Agents for Psoriasis</i>	
DOVONEX® PSORIATEC®	TACLONEX®
<i>Non-Ergot Dopamine Receptor Agonists</i>	
REQUIP® REQUIP DOSE PACK®	MIRAPEX® NEUPRO®

5. **Old Business**

No old business.

6. **New Business**

P&T would like to review updated data regarding the Medicaid Pharmacy Program and PDL related savings.

Several members had questions regarding managed care programs and the impact to Medicaid and the PDL.

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

Receptor Selective NSAID's

Multiple Sclerosis Agents

Combination Benzoyl Peroxide/Clindamycin Products

Topical Retinoids

Alpha Blockers for BPH

Topical Agents for Psoriasis

Non-Ergot Dopamine Receptor Agonists

8. **Closing Comments**

The next meeting will be held on Wednesday, November 7, 2007 at 4:00 p.m. at the same location.

9. **Adjournment**

The meeting adjourned at 5 p.m.